New drugs require effort, investment and risk. But thanks to the weakness of governments, in the face of the lobbying from Big Pharma, we now have a regulatory system that rewards slick marketing over true innovation. We know these marketing strategies work, because a $600 billion industry wouldn’t spend tens of billions on them if they didn’t. It’s also clear that marketing has better returns than research, because the drugs industry spends more on marketing than on R&D.

…and these confused priorities are one of the reasons we haven’t yet found an effective treatment for Alzheimer’s, says Bad Science author Ben Goldacre


  1. motionandrest reblogged this from timesopinion
  2. timesopinion posted this

Loading posts...